Fifty 1 Labs and UAV Corp Unveil AI-Driven Strategy for NASDAQ Uplisting
Fifty 1 Labs, Inc. and UAV Corp announce a strategic plan to achieve a $50 million valuation and uplist to NASDAQ, leveraging AI in drug repurposing and functional medicine.
Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) have announced a bold, AI-driven strategy aimed at reaching a $50 million valuation and securing an uplisting to the NASDAQ Capital Market. This strategic move underscores the companies' commitment to revolutionizing the functional medicine and biotechnology sectors through innovative AI applications.
The plan includes a $1 million R&D initiative focused on discovering repurposed treatments by May 2026, alongside the launch of a digital platform by July 31, 2025. Additionally, the companies are eyeing biotech acquisitions in the $5–10 million range and plan to host a shareholder event in Q3 2025. With a leadership team that includes Nobel laureate Dr. James Orbinski and NFL veteran Brandon Spikes, Fifty 1 Labs is poised to make significant strides in the $320.6 billion functional medicine market.
Backed by a $350,000 insider investment and leadership salary deferrals, the initiative reflects a strong internal belief in the company's direction and potential. The focus on AI-powered healthcare solutions and drug repurposing positions Fifty 1 Labs and UAV Corp at the forefront of personalized medicine and biotech innovation.
For further details, visit https://fifty1labs.com/.